BENEIN/KAIST: Preclinical Tumor Cell Re-differentiation Research (2024–2025)
Under development
This page is a placeholder under scientific review. Do not treat it as a complete or clinically validated summary until it is expanded with primary references.
Note: This is preclinical systems-biology research, not an approved therapy and not evidence that cancer can currently be "reversed" in patients.
BENEIN Platform (Boolean Network Inference and Control)
- Digital twin of differentiation; master regulator discovery; control strategy
Master Regulators (Colon Cancer)
- MYB, HDAC2, FOXA2 — roles in dedifferentiation and growth
Evidence Summary
- Cell lines (HCT‑116, HT‑29, CACO‑2): re‑differentiation to enterocyte‑like state
- Mouse models: tumor reduction; safety profile
- Transcriptomics: convergence to normal‑like gene expression
The primary study introduced single-cell Boolean network inference and control (BENEIN), applied it to human large-intestinal single-cell transcriptome data, and identified MYB, HDAC2, and FOXA2 as regulators whose combined inhibition pushed colorectal cancer models toward a more enterocyte-like state.This is promising biology, but it remains a model-system result. Sources: [1]
Critical Transition (“Tipping Point”) & REVERT
- Identification of unstable transition state; intervention switches
Clinical Development
- No approved clinical use.
- No patient benefit has been demonstrated.
- Any translational path would require target validation, delivery strategy, toxicity studies, and clinical trials.
Implications
- Paradigm shift vs cytotoxic therapies; combinations; prevention potential
References
- Gong JR, Lee CK, Kim HM, et al. Control of Cellular Differentiation Trajectories for Cancer Reversion. Advanced Science. 2025;12(3). doi:10.1002/advs.202402132. PMID:39661721.